BioLife Solutions Inc (BLFS)vsResMed Inc (RMD)
BLFS
BioLife Solutions Inc
$29.15
-3.67%
HEALTHCARE · Cap: $1.36B
RMD
ResMed Inc
$198.99
-1.86%
HEALTHCARE · Cap: $31.68B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 5347% more annual revenue ($5.54B vs $101.66M). RMD leads profitability with a 27.4% profit margin vs -2.9%. RMD appears more attractively valued with a PEG of 1.23. RMD earns a higher WallStSmart Score of 74/100 (B).
BLFS
Avoid30
out of 100
Grade: F
RMD
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-9.0%
Fair Value
$20.42
Current Price
$29.15
$8.73 premium
Margin of Safety
-27.2%
Fair Value
$204.13
Current Price
$198.99
$5.14 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.7% year-over-year
Strong operational efficiency at 35.3%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 0.1%
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : BLFS
The strongest argument for BLFS centers on Debt/Equity, Altman Z-Score, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.
Bear Case : BLFS
The primary concerns for BLFS are Market Cap, Operating Margin, PEG Ratio.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
BLFS profiles as a growth stock while RMD is a mature play — different risk/reward profiles.
BLFS carries more volatility with a beta of 1.94 — expect wider price swings.
BLFS is growing revenue faster at 24.7% — sustainability is the question.
RMD generates stronger free cash flow (520M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (74/100 vs 30/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?